Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.56 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 0.47 |
| ▸ | MMP1 known ✓ | P03956 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.49 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.49 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18321716 | 1.00 | SLC7A5 (0.56) | SLC7A5ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL594131 | 1.00 | SLC7A5 (0.56) | SLC7A5ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL237073 | 1.00 | SLC7A5 (0.56) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL314142 | 0.98 | SLC7A5 (0.58) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL594132 | 0.98 | SLC7A5 (0.58) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL1221379 | 0.98 | SLC7A5 (0.58) | SLC7A5ALPIPKMPTGS1XIAP | |
| Acetic Acid SCHEMBL7710564 | 0.97 | SLC7A5 (0.56) | SLC7A5ALPIPKMPTGS1XIAP | |
| Benzophenone SCHEMBL1679294 | 0.91 | SLC7A5 (0.56) | SLC7A5ALPIPKMPTGS1XIAP | |
| Benzophenone SCHEMBL1679572 | 0.91 | SLC7A5 (0.56) | SLC7A5ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL27782845 | 0.91 | SRR (0.51) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 432 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119528812-B | Double amino acid-genipin derivative and preparation method and application thereof | 广东工业大学 | 2025-06-03 | — | — | CN | claimed |
| CN-119528812-A | Double amino acid-genipin derivative and preparation method and application thereof | 广东工业大学 | 2025-02-28 | — | — | CN | claimed |
| CN-119504883-A | Synthesis method of RNA monomer intermediate 2' -fluoro-nucleoside modifier | 安徽信佰生物医药科技有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-118007135-A | Corrosion inhibition method for inhibiting metal corrosion in sulfur-containing medium | 福建理工大学 | 2024-05-10 | — | — | CN | claimed |
| CN-114644682-A | Preparation method of bortezomib | 海南双成药业股份有限公司 | 2022-06-21 | — | — | CN | claimed |
| CN-113402584-A | Synthetic method of intermediate LND1067-L1 of antibody-coupled drug linker | 联宁（苏州）生物制药有限公司 | 2021-09-17 | — | — | CN | claimed |
| CN-105061230-B | Method for preparing dapoxetine hydrochloride | 康普药业股份有限公司 | 2017-04-26 | — | — | CN | claimed |
| US-12612429-B2 | Derivatives of dolaproine-dolaisoleuine peptides | AGENSYS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-3801553-B1 | PRODRUGS OF FULVESTRANT | KASHIV BIOSCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20260000775-A1 | a4ß1/7 INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4643877-A1 | COMPOSITION OF CD40-BINDING MOLECULE AND PHARMACEUTICAL USE THEREOF | Suzhou Suncadia Biopharmaceuticals Co., Ltd. (CN) | 2025-11-05 | — | — | EP | disclosed |
| EP-0048763-B1 | SULFUR-CONTAINING ACYLAMINO ACIDS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1985-11-06 | — | — | EP | disclosed |
| US-4425333-A | HYPOTENSIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1984-01-10 | — | — | US | disclosed |
| EP-0058918-A1 | Aza analogs of aminoacid derivatives as antihypertensives | MERCK & CO. INC. (US) | 1982-09-01 | — | — | EP | disclosed |
| EP-0007477-B1 | 1-(3-MERCAPTO-2-METHYLPROPANOYL)PROLYL AMINO ACID DERIVATIVES AND SALTS THEREOF, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | Dainippon Pharmaceutical Co., Ltd. (JP) | 1982-04-28 | — | — | EP | disclosed |
| EP-0048763-A1 | SULFUR-CONTAINING ACYLAMINO ACIDS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1982-04-07 | — | — | EP | disclosed |
| US-4248883-A | ANTIHYPERTENSION AGENTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1981-02-03 | — | — | US | disclosed |
| EP-0007477-A1 | 1-(3-Mercapto-2-methylpropanoyl)prolyl amino acid derivatives and salts thereof, processes for their preparation, and pharmaceutical compositions containing such compounds | Dainippon Pharmaceutical Co., Ltd. (JP) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612429-B2 | Derivatives of dolaproine-dolaisoleuine peptides | DDOST, NGLY1, GRPR | PTGS1 1996/4885HDAC8 2876/4885MMP1 4362/4885 |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | FCGR2A, FCGR3B, BCL3 | PTGS1 3493/4885HDAC8 234/4885MMP1 2690/4885 |
| US-20260000775-A1 | a4ß1/7 INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ITGB1, ITGB4, ITGA4 | PTGS1 3842/4885HDAC8 1111/4885MMP1 2476/4885 |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | PTGS1 3843/4885HDAC8 3594/4885MMP1 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.